Dr. Yu Qiang: Facing Industry Changes and Embracing the Future of AI

Categories:Company News
Author:
Origin:
Time of issue:2024-03-22
Views:0

(Summary description)Recently, the 9th BIOCHINA (EBC) E-commerce Biotech Industry Conference was held at the Suzhou International Expo Center. Dr. Yu Qiang, founder and CEO of Shengshi Taike and Secretary General of Xinyao Club, participated in this conference and planned the "Small Molecule Innovative Drug Research and Development Forum". More than ten outstanding representatives from the industry were specially invited to discuss new technologies and targets of small molecule drugs, and explore with on-site guests how small molecules can play an important role in future drug research and development to better meet clinical needs.

Dr. Yu Qiang: Facing Industry Changes and Embracing the Future of AI

(Summary description)Recently, the 9th BIOCHINA (EBC) E-commerce Biotech Industry Conference was held at the Suzhou International Expo Center. Dr. Yu Qiang, founder and CEO of Shengshi Taike and Secretary General of Xinyao Club, participated in this conference and planned the "Small Molecule Innovative Drug Research and Development Forum". More than ten outstanding representatives from the industry were specially invited to discuss new technologies and targets of small molecule drugs, and explore with on-site guests how small molecules can play an important role in future drug research and development to better meet clinical needs.

Categories:Company News
Author:
Origin:
Time of issue:2024-03-22
Views:0

Recently, the 9th BIOCHINA (EBC) E-commerce Biotech Industry Conference was held at the Suzhou International Expo Center. Dr. Yu Qiang, founder and CEO of Shengshi Taike and Secretary General of Xinyao Club, participated in this conference and planned the "Small Molecule Innovative Drug Research and Development Forum". More than ten outstanding representatives from the industry were specially invited to discuss new technologies and targets of small molecule drugs, and explore with on-site guests how small molecules can play an important role in future drug research and development to better meet clinical needs.

After the meeting, Dr. Yu Qiang also accepted an exclusive interview in the live broadcast room of Yimao, sharing and exchanging his experience of participating in the conference, the development of the enterprise, and the future trends of the industry.

The following text content is a later excerpt and organization:

Yimao Live Room: How many times have you participated in BIOCHINA this year? Could you please introduce the theme and content shared during this conference?
Yu Qiang: For the second time, last year I participated as a sharing guest in the Peking University Alumni Entrepreneurship Forum. I participated in this conference as the founder of Shengshi Taike and the secretary general of Xinyao Club, and collaborated with the Yimao Industry Conference to plan the "Small Molecule Drug Innovation Research and Development Theme Forum". Today is March 14th (the day of the conference), and it is also a special holiday - π Day (International Mathematical Festival). The English mathematics for mathematics comes from Greek, which literally means "learn whatever you do". So today we have specially invited several outstanding representatives from the industry to learn about new technologies and targets of small molecule drugs together, and discuss with the guests how small molecules can play an important role in future drug research and development to better meet clinical needs.

Yimao Live Room: What have been the changes in your track over the past year, and what breakthroughs have your company made?
Yu Qiang: The recent emergence of the text generated video model Sora has pushed the discussion about generative artificial intelligence (AI) to a new height. At the same time, artificial intelligence (AI) has also brought tremendous changes to the field of drug development. Last year, many international pharmaceutical companies made significant investments in artificial intelligence technology, including equity investments, partnerships with AI pharmaceutical companies, and establishing internal research and development teams. Biotech also hopes to leverage advanced AI technology to screen and optimize candidate drugs with unprecedented efficiency, accelerating the discovery and development process of new drugs.

Another major change comes from the GLP-1 class of drugs that have become popular due to their "weight loss miracle drugs". From the perspective of differentiated competition and patient compliance, everyone is trying to expand the market space of GLP-1 drugs from peptide based injection drugs to small molecule oral drugs. At present, multinational pharmaceutical companies led by Pfizer and Eli Lilly are moving towards this "no man's land", and there are also a number of innovative pharmaceutical companies entering the domestic market. For example, our company has laid out a drug of this type in our research and development pipeline.
In the field of DPP-4, another popular hypoglycemic target that complements GLP-1, our company's original new drug Sengliptin (formerly known as Shenggliptin), which has been grinding for ten years, was accepted by the National Medical Products Administration at the beginning of last year. With its listing approaching, the company will also enter the stage of commercialization.

Yimao Live Room: How do you view the future development pattern of the biopharmaceutical industry?

Yu Qiang: There will be several obvious trends in the development of the biopharmaceutical industry in the future:
The first is the deep application of information technology such as artificial intelligence (AI) in the field of biomedicine, which was just mentioned. Artificial intelligence+biopharmaceuticals will be applied in many sub fields, such as new drug development, medical image analysis, disease prediction and prevention, intelligent diagnosis, precision medicine, etc., and it is expected to reshape the current status of biopharmaceutical research and industry.

Next is the update and iteration of small molecule technology, keeping up with the times, which is also the theme we discussed in today's special session. Especially thanks to the extensive exploration and application of artificial intelligence (AI) technology platforms in the field of small molecule drug development, people are able to more effectively discover new targets for small molecule inhibitors and design rational drugs, thereby accelerating new drug development. Therefore, in the future, small molecule drugs will still occupy a significant proportion in the development of new drugs.

Speaking of the exploration and application of artificial intelligence in the field of biomedicine, a sub forum on "Computational Medicine and Virtual Clinical Trials" was held today at the Suzhou Innovative Pharmaceutical Medicine Conference in China. Guests from various sectors, including government, enterprises, and hospitals, were invited to come together to share and discuss. Dr. Yu Qiang provided suggestions and suggestions on the industrial landing and cross-border cooperation of AI technology during the roundtable discussion.

The landing of AI technology industry requires the accumulation of sufficient high-quality data, which goes beyond successful case data. Failed case data may be more valuable for drug research and clinical trials. At the same time, data needs to achieve "same text, same track, same degree, same system, same ethics, and same domain". In the early stage of AI technology development, there are many flowers blooming, but it is necessary to establish unified industry standards as soon as possible to achieve data sharing. At the same time, unified industry standards also facilitate cooperation and communication between industries and cross industries. Secondly, the content of industry landing, such as virtual clinical, needs to be recognized by the National Drug Evaluation Center, so they should also accept these technologies as soon as possible. Finally, in addition to national medical insurance and patients, commercial medical insurance should also be promoted to pay for AI technology landing products, such as the application of AI technology in disease prediction and prevention, which can allow more healthy people to purchase commercial medical insurance.

When it comes to cross-border cooperation between AI technology and biopharmaceuticals, Dr. Yu Qiang believes that the first step is for both parties to have a deep understanding, in order to generate sufficient trust, and finally achieve win-win cooperation driven by the common interests of business cooperation.

Previous: Shengshi Taike has once again been listed on the "Top 50 Most Influential Medical and Health Enterprises in China" list

Next: World diabetes Day | Benefit diabetes Patients with Source Innovation

Previous: Shengshi Taike has once again been listed on the "Top 50 Most Influential Medical and Health Enterprises in China" list

Next: World diabetes Day | Benefit diabetes Patients with Source Innovation

Shengshi Taike: Exchange 'One Promise, One Thousand Gold' for 'Dreams Come True'

Introduction: Adhere to our original aspiration, forge ahead, and let our dreams shine into reality. The rapid development of Suzhou Industrial Park is the result of generations of park residents' continuous efforts, and also embodies the strength of each enterprise's rooting and growth. Enterprises are witnesses, but also participants. In the park, one group after another of enterprises have run the "upward trend" with their own "hard skills", using abundant vitality as ink and strong resilience as pen, writing a wonderful chapter of "striving for thirty years and building dreams towards the future". On the occasion of 15 years of rooting in Suzhou Industrial Park, Shengshi Taike Biopharmaceutical Technology (Suzhou) Co., Ltd. has reached a major development milestone - the company's first independently developed Class 1 innovative drug, sitagliptin phosphate tablets, has been approved for listing in China. The founder and CEO of Shengshi Taike, Yu Qiang, wrote a poem with deep emotion: "The trees and trees are all singing in heaven, and the colors are shining in the hall. The morning sun shines on the clouds, and the prosperous era welcomes the sunrise The original intention of entrepreneurship and the passion for innovation are intertwined at this moment into a beautiful story of the "two-way rush" between the park and talents. The successful approval of sengliptin for listing is due to the entrepreneurial fertile ground of Suzhou and the park, as well as the strong support of many departments. It is also a way to repay the park's pro business services with our innovative drugs, "said Yu Qiang. Since settling in the park in 2010, Shengshi Taike has been based in Suzhou and has a global perspective, focusing on the research and production of small molecule innovative drugs. With an integrated drug research and development technology platform and diversified business vision, it has built a rich pipeline of innovative drugs covering areas such as blood sugar reduction, anti-cancer, and autoimmune。 Funds - the 'first pot of gold' that leverages innovation leverage In 2010, with rich scientific research and practical experience in the field of pharmaceutical research and development, Yu Qiang and partner Ding Juping established Shengshi Taike in Suzhou Biomedical Industry Park (BioBAY), committed to the research and industrialization of breakthrough small molecule innovative drugs for therapeutic purposes. "China is a big country with diabetes in the world, and the number of patients with diabetes is the first in the world. In 2008, I heard the news that China began to attach importance to the biomedical industry. Around 2010, I decided to bring my initial research and development achievements, raise funds, form a team, and return to China to make a new class of hypoglycemic drugs." Recalling more than a decade ago, Yu Qiang still remembers. The decision to return to China and start a business in the park was impressed by the numerous emails exchanged. At that time, I was still in the United States and consulted the park government about entrepreneurship issues through email. The response I received was not only fluent in English, but also highly professional. The fact has proven that my initial choice was the right one The beginning of everything is difficult. Even if the conditions for starting a business in China are relatively mature, for a new drug research and development company in the start-up stage, the challenges it faces can be imagined. Shortage of funds is the first problem. Fortunately, the park provides very strong financial support to leading talents, "said Yu Qiang. When he settled in 2010, the park could offer a" big gift package "of up to 10 million yuan to leading talents in the biopharmaceutical field, including housing subsidies, rent reductions, subsidized loans, start-up capital, etc. More importantly, the predecessor of Yuanhe Holdings, Zhongxin Venture Capital, gave us 6.5 million yuan in angel investment, which can be said to be a" timely help "for start-up companies. Later, the company's new drugs were successively shortlisted for the national "Twelfth Five Year Plan", "Thirteenth Five Year Plan" and "Major New Drug Creation" special projects, and were included in the national key support track, further obtaining financial support. The guidance fund and leading venture capital of the park's enterprise development service center have provided financing support at different stages of Shengshi Taike's development. With the guidance of government industry funds, they have also attracted more social capital to invest and jointly support enterprise innovation. I have always believed that it is the '1' given by the park that leads to the '0' increase in social capital in the future, "Yu Qiang said with a smile. Funds support the growth of enterprises and drive industrial development. At present, Shengshi Taike has built a rich drug pipeline, with product distribution fr

2025-01-07

Milestones | Shengshi Taike's new generation DPP-4 inhibitor approved for market launch

Today, the official website of the National Medical Products Administration (NMPA) of China announced that Shengshi Taike's independently developed Class 1 innovative drug, saxagliptin phosphate tablets (formerly known as saxagliptin phosphate tablets), has been approved for market in China. This is a new generation of highly selective DPP-4 inhibitor, which is suitable for improving the blood sugar control of adult type 2 diabetes patients. According to the Guidelines for the Prevention and Treatment of Type 2 diabetes in China, the prevalence of diabetes among adults in China has risen to 11.2%, of which more than 90% are type 2 diabetes. In order to meet the huge clinical demand, some new drugs with different mechanisms of action from traditional oral hypoglycemic drugs have emerged in recent years. Dipeptidyl peptidase-4 (DPP-4) inhibitors are one of them. They not only improve hyperglycemia, but also are not easy to induce hypoglycemia and weight gain. They have the characteristics of rapid oral absorption, long half-life, and long-lasting effect, and are known as "smart" hypoglycemic drugs. Currently, they have been recommended by many domestic and foreign guidelines. As a new generation of highly selective DPP-4 inhibitor independently developed by Shengshi Taike, sengliptin has been continuously selected for the national "Major New Drug Development" special projects in the 12th and 13th Five Year Plans. Due to the excellent data demonstrated in the first phase clinical trial of the best product in the market, it was exempted from phase 2 clinical trials and directly entered phase 3 clinical trials, pioneering the "exemption from two to three" clinical trials in the field of this drug. The results of the phase III clinical trial of Sengliptin led by Professor Ji Linong, director of the Endocrinology Department of Peking University People's Hospital and director of Peking University diabetes Center, showed that in the single drug treatment trial of Sengliptin, the reduction values of HbA1c in the 50mg and 100mg dose groups at the end of the 24th week were 1.08% and 1.07% respectively; In the treatment trial of sengliptin combined with metformin, the glycated hemoglobin decreased by 1.23% and 1.17% in the 50mg and 100mg dose groups at the end of the 24th week, respectively. Meanwhile, both sets of experimental data showed that patients with higher blood sugar levels experienced a greater decrease in glycated hemoglobin levels. In addition to its excellent hypoglycemic effect, what is even more commendable is that in the comparison between the 100mg dose group (high-dose group) and the placebo group in the last 28 weeks, the incidence of adverse reactions of sengliptin is similar to that of the placebo group, and its safety further solves the common adverse reactions in marketed products. At present, metformin combined with leptin has become the main treatment scheme in the clinical application of treating type 2 diabetes. According to Sullivan's research report, by 2030, the market size of leptin in China will exceed 30 billion, with broad market prospects. Ding Juping, the co-founder and president of Shengshi Tyco, said: "I am very glad to see the company's self-developed product, Sengliptin Phosphate Tablets, has been approved for listing. This drug will be the best new hypoglycemic drug of its kind with half the effort and twice the treatment effect. I hope it will benefit the majority of diabetes patients in China as soon as possible after it is approved for listing." Dr. Yu Qiang, the founder and CEO of Shengshi Tyco, said: "Sengliptin's successful approval for listing benefits from Suzhou and the park as a fertile land for entrepreneurship and the strong support of many departments. It is also a" promise of gold "to use our innovative drugs to repay the business friendly services in Suzhou Park. At this moment, I would like to use an original poem to bless this new drug for its successful launch." Morimu's sounds of nature are listed in the palace. The morning light shines on the clouds, and the prosperous world welcomes the sunrise.

2024-12-05